Page 35 - CUA Absracts 2022_Fulldraft

Poster 2: BPH

MP-2.13. Table 1. Preoperative parameters, intraoperative
parameters, and perioperative outcomes
Parameters and outcomes Value, n (%)
HoLEP technology Conventional 26 (65%)
MOSES technology 14 (35%)
TM
Age yrs <70 4 (10%)
70–80 20 (50%)
>80 16 (40%)
Antiplatelet &/ Yes ASA 16 (40%)
anticoagulant medication Clopidogrel + 4 (10%)
ASA
Warfarin + ASA 2 (5%)
Rivaroxaban + 5 (12.5%)
ASA
No 13 (32.5%)
Preoperative blood Yes 2 units 3 (7.5%)
transfusion >2 units 2 (5%)
No 35 (87.5%)
Drop in Hgb, % Mean + SD 11+4%
Median drop in Hgb, % Conventional 6%
MOSES technology 6%
TM
MP-2.12. Figure 1. Change in IPSS, IPSS QoL, Qmax, and PVR for young (bold) Previous TURP Yes 28 (70%)
and elderly (grey) men undergoing Aquablation for LUTS/BPH at three years No 12 (30%)
followup. Prostate cancer Yes 2 (5%)
No 38 (95%)
counselling should, therefore, consider Aquablation as a treatment option Prostate volume, cc Mean + SD 120.2+47.5
for LUTS/BPH.
Resected prostate Mean + SD 88.7+42.2
weight, g
MP-2.13
Emergency holmium laser enucleation of the prostate: A novel Enucleation time, min Mean + SD 73.2+38.5
approach in the management of refractory hematuria of prostatic Morcellation time, min Mean + SD 13.2+7
origin Energy, KJ Mean + SD 135.2+73.2
Hazem Elmansy , Ahmed S. Zakaria , Moustafa Fathy , Ruba Abdul Hadi ,
1
1
1
1
Emmanuel Kawa , Loay Abbas , Shahrzad Keramati , Owen Prowse , Catheter time <24 hours 38 (95%)
1
1
1
1
Ahmed Kotb , Walid Shahrour 1 >24 hours 2 (5%)
1
1 Division of Urology, Department of Surgery, Northern Ontario School Postoperative hospital <24 hours 37 (92.5%)
of Medicine, Thunder Bay, ON, Canada stay
Introduction: Refractory hematuria secondary to prostatic disease typ- >24 hours 3 (7.5%)
ically resolves with conservative management; however, this condition Postoperative clot Yes 2 (5%)
may require hospitalization with extensive measures to control life-threat- retention No 38 (95%)
ening bleeding. The aim of this study was to report our initial experience
using holmium laser enucleation of the prostate (HoLEP) as an emergency Readmission Yes 1 (2.5%)
treatment in this clinical setting. No 39 (97.5%)
Methods: We conducted a retrospective review of all patients that pre-
sented to the emergency department with refractory hematuria of pros- Conclusions: Our initial experience demonstrates that emergency HoLEP
tatic origin from 2017–2021, for whom hospitalization and conservative may be an effective treatment for patients with refractory hematuria of
management failed to control bleeding. All emergency HoLEP procedures prostatic origin. Further studies are warranted to consolidate our results.
were performed by a single surgeon. Preoperative and intraoperative par-
ameters, as well as perioperative outcomes, were collected and analyzed.
Results: A total of 40 emergency HoLEP procedures were performed.
Our cohort had a mean prostate volume of 120.2+47.5 cc and a mean
resected weight of 88.7+42.2 g. Twenty-seven patients (67.5%) were on
anticoagulant or antiplatelet medications. Intraoperative parameters and
perioperative outcomes revealed a mean drop in hemoglobin of 11+4%
(Table 1). The urethral catheter was removed within one day in 95% of
patients with a successful trial of voiding. Moreover, 92.5% of patients
were discharged home within 24 hours of their procedure. Two patients
(5%) experienced clot retention, with a 2.5% overall readmission rate.
CUAJ • June 2022 • Volume 16, Issue 6(Suppl1) S33